LXEO vs. VCEL, IMCR, BEAM, RXRX, KYMR, FUSN, SANA, NMRA, VIR, and FDMT
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Vericel (VCEL), Immunocore (IMCR), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Lexeo Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 21.74%. Vericel has a consensus price target of $46.80, suggesting a potential upside of 5.45%. Given Lexeo Therapeutics' higher probable upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than Vericel.
Vericel received 329 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 61.99% of users gave Vericel an outperform vote.
In the previous week, Lexeo Therapeutics had 4 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Lexeo Therapeutics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.97 beat Lexeo Therapeutics' score of 0.57 indicating that Vericel is being referred to more favorably in the news media.
Vericel has a net margin of 0.22% compared to Lexeo Therapeutics' net margin of 0.00%. Vericel's return on equity of 0.21% beat Lexeo Therapeutics' return on equity.
Vericel has higher revenue and earnings than Lexeo Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Vericel beats Lexeo Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
